Nasopharyngeal Nonkeratinizing Carcinoma clinical trials at UC Health
1 in progress, 0 open to new patients
Sorry, in progress, not accepting new patients
This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
at UC Davis